Aims & Scope
The Journal of Parkinson’s Disease is dedicated to providing an open forum for original research in basic science, translational research and clinical medicine that will expedite our fundamental understanding and improve treatment of Parkinson’s disease. The journal is international and multidisciplinary and aims to promote progress in the epidemiology, etiology, genetics, molecular correlates, pathogenesis, pharmacology, psychology, diagnosis and treatment of Parkinson’s disease. It will publish research reports, reviews, short communications, and letters-to-the-editor and offers very rapid publication and affordable open access.
The full editorial board of the Journal of Parkinson's Disease can be found on its dedicated website here: Editorial Board.
Biomedical Reference Collection
Cabell's Guide or Directory
Chemical Abstracts Service (CAS)
Web of Science: Journal Citation Reports/Science Edition
Web of Science: Science Citation Index Expanded (SciSearch®)
Gold open access pricing
From 2023 onwards the Journal of Parkinson’s Disease has moved from its previous hybrid publication model to a true gold open access journal. Authors of accepted papers will be required to pay an open access fee of US$2000 / €2000 (ex. VAT if applicable) to publish under the CC BY-NC 4.0 license on acceptance for publication. Publishing under the CC BY 4.0 license is available at US$2400 / €2400 (ex. VAT if applicable). After an article is accepted for publication, the corresponding author will be informed regarding the open access options during the production stages. It could be that the open access fee of an article is waived completely due an institutional agreement IOS Press has with the corresponding authors' institution. Please check the institutional agreements page for details.
Waivers are available for corresponding authors from eligible countries as identified by Research4Life project. Other authors who envisage difficulties paying the article processing charge may appeal to the Editors-in-chief to discuss waiving the charge prior to submitting their article. Appeals submitted after review has been completed are rejected.
Articles published behind a paywall in the pre-2023 volumes are available only to institutions and individuals with access rights. However, the journal offers all authors the option to purchase open access publication for their article as part of the IOS Press Open Library, even after final publication. This means that the current version will be made freely available to anyone worldwide, indefinitely, under a Creative Commons license. This is also referred to as “gold” open access. Authors who submitted their article before 2023 and who now choose gold open access publication will be subject to an article publication charge of € 1250 / US$ 1450 for publication under the CC BY-NC 4.0 license or € 1850 / US$ 2080 for publication under the CC BY 4.0 license. Pricing is exclusive of possible taxes. Authors can purchase open access at any time through the order form link in their decision letter.
Green open access
Authors who did not make use of the gold open access option pre-2023 may still make their article freely available using self-archiving, also referred to as green open access. Authors may make their final accepted manuscript available for free download from their personal or institutional website or institutional archive. This model is free for the author.
This journal deposits all open access articles in PubMedCentral (PMC) as part of the IOS Press Open Library. If an author chooses to publish their paper with open access then the publisher will deposit the article in PMC upon publication.
New Co-Editor-in-Chief Appointed: A new co-Editor-in-Chief (EIC) joined the journal in May 2022. A heartfelt welcome to Lorraine Kalia, and huge thanks to the outgoing EIC Patrik Brundin. Read the news announcements here.
Social Media & Sign Ups: The Journal of Parkinson's Disease (JPD) is on Facebook and Twitter, with social media editor Rui Araújo, PhD
(University of Porto, Portugal) at the helm. Be sure to follow us and be part of the conversation! You can sign up to the JPD newsletter to receive alerts of new issues and other journal news via this link tiny.cc/JPDsignup & read the latest newsletter here.
Partnership with WPC: Since April 2020, JPD has partnered with the World Parkinson Coalition (WPC), an organization which fills a unique niche in the global Parkinson's community. The partnership will see our respective teams working together to give a platform to the latest developments in PD research. View the WPC website here.
Clinical Trials Highlights: At the start of 2019, a new journal section co-edited by Kevin McFarthing and Tanya Simuni was launched to raise awareness of the clinical trial landscape in Parkinson’s, promoting discussion and progress in the conduct and outcome of studies; view here.
Parkinson's Webinar Series: JPD works in partnership with The Cure Parkinson’s Trust and Van Andell Institute to produce a series of Quarterly Parkinson's Webinars. Discover more here. The topic of our latest webinar was World Parkinson Congress 2023 Highlights. Watch the webinar recording here.
JPD Open Access Special Issues: Abstracts of the 6th World Parkinson Congress, July 4–7, 2023, Barcelona, Spain - Vol.13, Iss.s2; Linking Immune Activation and Parkinson’s Disease - Vol.12, Iss.s1; Repairing the Parkinsonian Brain – Vol.11, Iss.s2; Digital Technology in PD Care & Research – Vol.11, Iss.s1; Clinical Care of Parkinson's – Vol.10, Iss.s1; Gut-Brain Axis in PD – Vol.9, Iss.s2 poses the question as to whether PD stars in the gut for all patients or a small subgroup; and PD 20 Years from Now – Vol.8, Iss.s1 addresses where Parkinson's research & treatment will be 20 years from now and you can read more in the mailing here.
Discover the contents of the latest journal issue:
Dietary Interventions in Parkinson’s Disease
Sabine Schootemeijer, Indy van der Berg, Karin Overbeek, Bastiaan R. Bloem, Nienke M. de Vries
Defining a Lewy Body: Running Up the Hill of Shifting Definitions and Evolving Concepts
Dragomir Milovanovic, Tim E. Moors
Addressing Comorbidities in People with Parkinson’s Disease: Considerations From An Expert Panel
Carl E. Clarke, Camille Carroll, Donald Grosset, Arshad Rather, Biju Mohamed, Miriam Parry, Prashanth Reddy, Robin Fackrell, Kallol Ray Chaudhuri
Characterization of Novel Human β-glucocerebrosidase Antibodies for Parkinson’s Disease Research
Alexandra Gehrlein, Tiffany Jong, Ellen Sidransky, Ravi Jagasia, Yu Chen